Rautou Pierre-Emmanuel

MD, PhD in vascular biology,
Prof. of Hepatology

[Rautou Pierre-Emmanuel @RautouE]

Our results just published in @jclinicalinvest demonstrate that microvesicles derived from erythrocytes are responsible for cardiovascular events occurring in patients with myeloproliferative neoplasms.
Congratulations to @poisson_johanne & the whole team
@parcc_inserm @Inserm

[EASL Education @EASLedu]

Ready to lead your own research group? 🔬

The science may be familiar but what about managing a team, securing funding, building a research programme and planning a sustainable career?🫣

The next episode of #TalkLiverToMe explores what research independence really looks like.

ℹ️https://t.co/jPQs44bqjB

@C_V_Schneider @CancerInflam @RautouE @Mandorf1 @IsraelsenMads @ZanettoAlberto

#LiverX

[EASLnews @EASLnews]

For early-career researchers and clinician-scientists, the move to independence brings new challenges: leadership, funding, team management, and long-term career planning.

Tune in to #TalkLivertoMe this Wednesday for an honest discussion on what nobody tells you about early academic leadership.

Read more: https://t.co/ecZ7ChZiIu

[Decision4Liver @Decision4Liver]

What happens before cirrhosis patients suddenly deteriorate?
Single-cell analysis reveals that monocytes lose energy before organ failure, a signal linked to infections, disease progression, and survival.

@ef_clif
🎥 Watch: https://t.co/ciZHdwSdS6

#cirrhosis #livertwitter

[Decision4Liver @Decision4Liver]

Live from our DECISION Investigator Meeting at #EASL2026: Project updates, clinical trial progress, and collaborative discussions with Paolo Caraceni & @RautouE
@ef_clif
@easlnews
#ClinicalTrials #cirrhosis

[EASLnews @EASLnews]

Meet @Decision4Liver at #EASLCongress 2026! Representatives Estefania Huergo, @RautouE and Frank Erhard Uschner will be discussing the project and answer all your questions!

📅 Wednesday, 27 May 13:45-14:15
📍Track Hub 6

Register to EASL Congress: https://t.co/7kROJ9gjCa

#LiverTwitter #LiverX

[Decision4Liver @Decision4Liver]

#EASL2026 is right around the corner!✨
join our Networking Session and meet @RautouE, Estefanía Huergo, and @UschnerFrank, who will present some exciting new DECISION research.
📍Cirrhosis and Complications Track Hub
📆Wednesday, 27 May
🕜13:45 - 14:15h
See you in Barcelona 🪭!

[The Baveno Cooperation: an EASL Consortium @BavenoCoop]

Panel 8 at #BavenoVIII: PSVD & Budd–Chiari syndrome 🗣️ Chairs: @VirginiaHdezGea, D. Valla
👥 Panelists: S.D. Murad, A. De Gottardi, K. Lamplicher, @MPraktiknjo, @RautouE, C. Sempoux, @drakashshukla3

Follow 🧵👇

[Jesus Bañales @JesusMBanales]

Today is a very sad day for the liver comunity 🥹

We lost a great hepatologist, and a visioner of research dissemination and education

Referent in @@EASLedu

It was great to work with you
We will miss you dear Ahmed 🌟💫🙏

[Decision4Liver @Decision4Liver]

Acute decompensation of cirrhosis carries high 90-day mortality, but prediction remains challenging.
Adding signatures of large extracellular vesicles may improve scores and prediction.
🎥 https://t.co/voCJW8FEh3

@ef_clif @RautouE @EASLnews @EuropeLiver
#LiverTwitter #vesicles

[Elliot Tapper @ebtapper]

Fair and balanced letter to the editor
@RautouE

[Decision4Liver @Decision4Liver]

New keynote out now!
🌟 Prof. Rubén Francés (@get_ruben) explains how LSECtin shapes immune tolerance and inflammation in advanced chronic liver disease.
Watch here: https://t.co/By1R4N28Fs
#cirrhosis #ACLF #LiverTwitter

[Decision4Liver @Decision4Liver]

New DECISION study in @JHepatology: maladaptive emergency granulopoiesis predicts poor outcomes in acutely #decompensatedcirrhosis.
This could guide early identification and novel therapies. https://t.co/2TdQonmXOP

#ACLF #Cirrhosis #LiverTwitter @EASLnews @ef_clif @EuropeLiver

[The Baveno Cooperation: an EASL Consortium @BavenoCoop]

🚨Just 10 days away ‼️
Join the VALDIG PSVD Meeting 2025 in Paris

🗓️ Dec 4–5 @ CNAM
💶 Onsite €150 | 💻 Online FREE
👉 Organized by EURO-VALDIG NET & FILFOIE
🔗 Registration → https://t.co/bNcGUdExzY...📘 Updated program below 👇
#LiverTwitter

[Decision4Liver @Decision4Liver]

That’s a wrap on our final DECISION GA!

From COMBAT & PROSPECT updates to forward-looking discussions and feedback, we’re proud of our shared achievements and motivated to keep advancing ACLF & decompensated cirrhosis research together.

#LiverTwitter

[EASLnews @EASLnews]

Catch up on this week's EASL Studio thought-provoking episode!
Experts debate the real-world utility of prognostic scores, the clarity (or confusion) created by multiple definitions, and whether the ACLF concept drives urgency, facilitates transplant access, or improves outcomes.

Watch here: https://t.co/XKFfLU7Ze1

@tom_marjot @ProfPaoloAngeli @BavenoCoop @VirginiaHdezGea @RautouE
#LiverTwitter #LiverX

[Decision4Liver @Decision4Liver]

Our final GA is a look back and forward - from major scientific milestones to future discoveries!
After a keynote by Prof. Rubén Francés, partners shared results on omics integration, biomarkers & systems medicine - and closed with a masterclass on data repositories. #cirrhosis

[EASL Education @EASLedu]

What’s the difference between acute decompensation & #ACLF?
Acute decompensation ≠ always ACLF.
👉 ACLF = decompensation + organ failure
👉 3 pathways:
1️⃣ Organ failure → ACLF
2️⃣ No organ failure but unstable → admit
3️⃣ Stable, no deterioration → no admission

@tom_marjot @ProfPaoloAngeli @BavenoCoop @VirginiaHdezGea @RautouE
#EASLStudio

[EASLnews @EASLnews]

Today's EASL Studio questions whether assigning the label “ACLF” to a deteriorating patient truly alters clinical decisions, or if focusing on the specifics of organ failure and reversibility is more useful.

See you tonight at 18:00 CEST on https://t.co/fB3Fsxtalk

@tom_marjot @ProfPaoloAngeli @BavenoCoop @VirginiaHdezGea @RautouE
#LiverTwitter #LiverX

[Elliot Tapper @ebtapper]

Trial of EUS vs TJ

Biopsy AND portal pressure

Huge win for EUS. The biopsy I buy. But 60% adequacy for portal pressure measures by TJ?

I don’t know about that